|
|
![]()
|
|
By Erin Harris, Editor-In-Chief, Cell & Gene
Time is flying, and as 2023 marches on, as many as 13 cell or gene therapies could be granted FDA approval by the end of the year.
|
|
|
By Hanson Koota, Blair Miller, Shannon Anderson, Keren Shani, Theresa Morley McLaughlin, and Nathan Buchwald, Trinity Life Sciences
This article examines in detail why the product-level drivers of uptake – including efficacy, burden of administration, and durability expectations – are crucial for maximizing revenue potential and market share, particularly in markets with multiple competitors.
|
|
|
Article
|
By Sean Walter, Sankalp Sethi, Prashant Khare, and Abhinay Manne,
ZS Associates, Inc.
Innovation in cell and gene therapies (CGTs) is leading to rapid growth in the space and transforming standards of care. Learn about the major considerations for developing CGT forecasts.
|
|
Article
|
By Jessica Merryfield,
Premier Research
Discover tips on operationalizing gene therapy studies in order to optimize site selection and patient recruitment and engagement.
|
|
Article
|
By Thomas VanCott, Ph.D.,
Catalent
The success of using viral vectors to deliver a molecular payload into a cell or replace defective genes with functional ones is an inflection point in the future of modern medicine.
|
|
Article
|
By Jaime Rain,
Kymanox Corporation
The revisions to EU Annex 1 set the stage for the future direction of the pharma/biotech industry. Explore some of the key takeaways and interesting changes for risk management and contamination control strategies.
|
|
Article
|
By Marwan Alsarraj and Mark White, Ph.D.,
Bio-Rad Laboratories, Inc.
Learn what industry experts have to say about how CDMOs are adding value through stability and development expertise, developing partnerships with innovators, and implementing the latest technologies.
|
|
White Paper
|
By Dr. Catherine Jomary,
IPS-Integrated Project Services
Learn more about the challenges that arise during the synthesis, purification, and encapsulation of mRNA.
|
|
Application Note
|
By Thiago Millen, Laura Chinn, Cameron Bardiving, Allison Vaughan, and Mark Rothenberg,
Jefferson Institute for Bioprocessing (JIB)
The goal of this study was to understand the impact of monitoring osmolality during an ultrafiltration/diafiltration (UF/DF) step prior to CEX capture of the monoclonal antibody Rituximab.
|
|
Article
|
RoosterBio
Learn about a novel method to obtain unique HUCPVs and how premium-quality hUC-MSCs drive innovative translational research.
|
|
Article
|
Premier Consulting
In recent years, the quantity of approvals for products and 505(b)(2) applications has risen, causing developers to map out their regulatory strategy as early as possible.
|
|
Article
|
Cytiva
The SARS-CoV-2 virus has changed the course of scientific research around messenger RNA (mRNA). Learn about mRNA manufacturing, the structure of a mRNA molecule, RNase-free considerations, and more.
|
|
Infographic
|
Waters Corporation
For biopharmaceutical organizations that need the power and performance of LC-MS for routine screening and MAM, we have designed the first SmartMS-enabled biopharma LC-MS solution. Learn more about connecting molecular attributes to product and process knowledge using the BioAccord System.
|
|
Virtual Event
|
Sartorius
Each of the diseases discussed is going to be different in the way it manifests, and the target cell arguably is going to be different as well. Strapps and Kalayoglu break it down disease by disease.
|
|
|
![]()
|
|
Have you heard of Life Science Leader?
Check it out today for access to candid interviews with top-tier executives on how they do business.
|
|
|
|
Connect With Cell & Gene:
|
![LinkedIn]()
![Twitter]()
|
|
|
|
|
|
|
|
